Market Cap 339.67M
Revenue (ttm) 5.82M
Net Income (ttm) 71.18M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 1,223.02%
Debt to Equity Ratio 0.12
Volume 1,325,700
Avg Vol 1,507,448
Day's Range N/A - N/A
Shares Out 57.18M
Stochastic %K 24%
Beta 1.35
Analysts Strong Sell
Price Target $18.86

Company Profile

Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV...

Industry: Biotechnology
Sector: Healthcare
Phone: 646 813 4701
Address:
6555 Carnegie Avenue, 4th Floor, Cleveland, United States
LorriPurdy207
LorriPurdy207 Aug. 19 at 9:13 AM
$AGQ $BIDU $NUVB $ABEO AGQ provides leveraged silver exposure, Baidu benefits from Chinese AI and cloud growth, Nuvation Bio remains focused on oncology development, and Abeona advances cell and gene therapies. I'm watching silver prices, Chinese demand, clinical milestones, regulatory catalysts, and funding.
0 · Reply
DeanPresto849
DeanPresto849 Aug. 19 at 7:15 AM
$AGQ $BIDU $NUVB $ABEO AGQ provides leveraged silver exposure, Baidu benefits from Chinese AI and cloud growth, Nuvation Bio remains focused on oncology development, and Abeona advances cell and gene therapies. I'm watching silver prices, Chinese demand, clinical milestones, regulatory catalysts, and funding.
0 · Reply
commoncentsinvestor
commoncentsinvestor Aug. 19 at 1:23 AM
$ABEO Whether Abeona Therapeutics Inc (NASDAQ: ABEO) is undervalued depends on whether you weigh Wall Street's future product expectations or current commercial execution. Trading around $6.80 to $7.20, consensus analyst price targets average roughly $18.85 to $19.71, suggesting significant upside if its gene therapy rollouts succeed. However, fundamental metrics show a mixed and speculative picture.Analyst and Intrinsic OptimismHigh Price Targets: Wall Street consensus forecasts a strong buy potential with targets ranging from a low of $14 up to $28, implying substantial percentage upside from current levels.Model-Based Upside: Certain intrinsic value models point to deep undervaluation based on long-term discounted cash flows of their therapeutic pipelin
0 · Reply
acm20
acm20 Aug. 19 at 12:00 AM
$ABEO "A buy signal was issued from a pivot bottom point on Monday, August 17, 2026, and so far it has risen 3.70%." "The stock lies in the lower part of a very wide and strong rising trend in the short term, and this may normally pose a very good buying opportunity. If the lower trend floor at $5.97 is broken, it will firstly indicate a slower rate of rising, but may also be an early warning for a trend shift. Given the current short-term trend, the stock is expected to rise 24.71% during the next 3 months and, with a 90% probability hold a price between $7.44 and $9.85 at the end of this 3-month period."
0 · Reply
TragicRain
TragicRain Aug. 18 at 8:39 PM
$ABEO - Happy Happy dance.......
0 · Reply
tmoney4572
tmoney4572 Aug. 18 at 8:14 PM
0 · Reply
Rolo2024
Rolo2024 Aug. 18 at 7:09 PM
$ABEO Better up than down. Let’s see if we can finally turn this ship around after recent earnings report.
0 · Reply
stinkypoopypantz
stinkypoopypantz Aug. 18 at 7:09 PM
$ABEO waiting for the news on this pump?!
1 · Reply
jimmy18000
jimmy18000 Aug. 18 at 7:03 PM
$ABEO moving north after couple days of take down.
1 · Reply
TerriFowler457
TerriFowler457 Aug. 18 at 11:53 AM
$ABEO $SE $POET $ONON Abeona advances cell and gene therapies, Sea benefits from e-commerce and digital-financial growth in Southeast Asia, POET develops optical-engine and photonic technologies, and On Holding benefits from premium athletic-footwear demand. I'm watching clinical catalysts, GMV growth, AI networking, and consumer spending.
0 · Reply
Latest News on ABEO
Abeona Therapeutics reports Q2 EPS (35c), consensus (25c)

2026-08-17T07:59:52.000Z - 2 days ago

Abeona Therapeutics reports Q2 EPS (35c), consensus (25c)


Abeona Therapeutics Earnings Call Transcript: Q2 2026

Aug 13, 2026, 8:30 AM EDT - 5 days ago

Abeona Therapeutics Earnings Call Transcript: Q2 2026


Abeona Therapeutics Quarterly report: Q2 2026

Aug 13, 2026, 8:30 AM EDT - 5 days ago

Abeona Therapeutics Quarterly report: Q2 2026


Abeona Therapeutics Earnings release: Q2 2026

Aug 13, 2026, 8:30 AM EDT - 5 days ago

Abeona Therapeutics Earnings release: Q2 2026


Abeona Therapeutics Transcript: AGM 2026

Jun 12, 2026, 9:00 AM EDT - 2 months ago

Abeona Therapeutics Transcript: AGM 2026


Abeona Therapeutics Slides: Investor presentation

Jun 10, 2026, 7:00 AM EDT - 2 months ago

Abeona Therapeutics Slides: Investor presentation


Abeona Therapeutics Earnings Call Transcript: Q1 2026

May 13, 2026, 8:30 AM EDT - 3 months ago

Abeona Therapeutics Earnings Call Transcript: Q1 2026


Abeona Therapeutics Earnings release: Q1 2026

May 13, 2026, 8:30 AM EDT - 3 months ago

Abeona Therapeutics Earnings release: Q1 2026


Abeona Therapeutics Quarterly report: Q1 2026

May 13, 2026, 8:30 AM EDT - 3 months ago

Abeona Therapeutics Quarterly report: Q1 2026


Abeona Therapeutics Slides: Q1 2026

May 13, 2026, 8:30 AM EDT - 3 months ago

Abeona Therapeutics Slides: Q1 2026


Abeona Therapeutics reports Q1 EPS (30c), consensus (39c)

2026-05-13T12:17:05.000Z - 3 months ago

Abeona Therapeutics reports Q1 EPS (30c), consensus (39c)


Abeona Therapeutics Proxy statement: Proxy filing

May 4, 2026, 8:00 AM EDT - 3 months ago

Abeona Therapeutics Proxy statement: Proxy filing


Abeona Therapeutics Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 4 months ago

Abeona Therapeutics Proxy statement: Proxy filing


Abeona Therapeutics Proxy statement: Proxy filing

Apr 17, 2026, 8:00 AM EDT - 4 months ago

Abeona Therapeutics Proxy statement: Proxy filing


Abeona Therapeutics Slides: Corporate presentation

Apr 14, 2026, 7:00 AM EDT - 4 months ago

Abeona Therapeutics Slides: Corporate presentation


Abeona Therapeutics Earnings Call Transcript: Q4 2025

Mar 17, 2026, 8:30 AM EDT - 5 months ago

Abeona Therapeutics Earnings Call Transcript: Q4 2025


Abeona Therapeutics Annual report: Q4 2025

Mar 17, 2026, 8:30 AM EDT - 5 months ago

Abeona Therapeutics Annual report: Q4 2025


Abeona Therapeutics Earnings release: Q4 2025

Mar 17, 2026, 8:30 AM EDT - 5 months ago

Abeona Therapeutics Earnings release: Q4 2025


Abeona Therapeutics announces employee inducement grants

2025-12-31T12:35:26.000Z - 8 months ago

Abeona Therapeutics announces employee inducement grants


Abeona Therapeutics appoints Mohamad Tabrizi as CBO

2025-12-15T12:36:04.000Z - 8 months ago

Abeona Therapeutics appoints Mohamad Tabrizi as CBO


Abeona Therapeutics reports employee inducement grants

2025-12-01T12:35:41.000Z - 9 months ago

Abeona Therapeutics reports employee inducement grants


Abeona Therapeutics Earnings Call Transcript: Q3 2025

Nov 12, 2025, 8:30 AM EST - 9 months ago

Abeona Therapeutics Earnings Call Transcript: Q3 2025


Abeona Therapeutics Quarterly report: Q3 2025

Nov 12, 2025, 8:30 AM EST - 9 months ago

Abeona Therapeutics Quarterly report: Q3 2025


Abeona Therapeutics Earnings release: Q3 2025

Nov 12, 2025, 8:30 AM EST - 9 months ago

Abeona Therapeutics Earnings release: Q3 2025


Abeona Therapeutics reports Q3 EPS (10c), consensus (34c)

2025-11-12T12:36:04.000Z - 9 months ago

Abeona Therapeutics reports Q3 EPS (10c), consensus (34c)


Abeona Therapeutics sees cash runway for over two years

2025-11-12T12:35:51.000Z - 9 months ago

Abeona Therapeutics sees cash runway for over two years


Abeona Therapeutics Earnings Call Transcript: Q2 2025

Aug 14, 2025, 7:30 AM EDT - 1 year ago

Abeona Therapeutics Earnings Call Transcript: Q2 2025


Abeona Therapeutics Earnings release: Q2 2025

Aug 14, 2025, 7:30 AM EDT - 1 year ago

Abeona Therapeutics Earnings release: Q2 2025


Abeona Therapeutics Quarterly report: Q2 2025

Aug 14, 2025, 7:30 AM EDT - 1 year ago

Abeona Therapeutics Quarterly report: Q2 2025


Abeona Therapeutics Earnings Call Transcript: Q1 2025

May 15, 2025, 7:00 AM EDT - 1 year ago

Abeona Therapeutics Earnings Call Transcript: Q1 2025


Abeona Therapeutics Earnings release: Q1 2025

May 15, 2025, 7:00 AM EDT - 1 year ago

Abeona Therapeutics Earnings release: Q1 2025


Abeona Therapeutics Quarterly report: Q1 2025

May 15, 2025, 7:00 AM EDT - 1 year ago

Abeona Therapeutics Quarterly report: Q1 2025


US FDA approves Abeona's skin disorder therapy

Apr 29, 2025, 6:06 AM EDT - 1 year ago

US FDA approves Abeona's skin disorder therapy


Abeona Therapeutics Proxy statement: Proxy Filing

Apr 9, 2025, 8:00 AM EDT - 1 year ago

Abeona Therapeutics Proxy statement: Proxy Filing


Abeona Therapeutics Earnings Call Transcript: Q4 2024

Mar 20, 2025, 7:30 AM EDT - 1 year ago

Abeona Therapeutics Earnings Call Transcript: Q4 2024


Abeona Therapeutics Earnings release: Q4 2024

Mar 20, 2025, 7:30 AM EDT - 1 year ago

Abeona Therapeutics Earnings release: Q4 2024


Abeona Therapeutics Annual report: Q4 2024

Mar 20, 2025, 7:30 AM EDT - 1 year ago

Abeona Therapeutics Annual report: Q4 2024


Abeona Therapeutics Earnings Call Transcript: Q3 2024

Nov 14, 2024, 7:30 AM EST - 1 year ago

Abeona Therapeutics Earnings Call Transcript: Q3 2024


Abeona Therapeutics Quarterly report: Q3 2024

Nov 14, 2024, 7:30 AM EST - 1 year ago

Abeona Therapeutics Quarterly report: Q3 2024


Abeona Therapeutics Earnings release: Q3 2024

Nov 14, 2024, 7:30 AM EST - 1 year ago

Abeona Therapeutics Earnings release: Q3 2024


Abeona Therapeutics Proxy statement: Proxy Filing

Nov 12, 2024, 7:00 AM EST - 1 year ago

Abeona Therapeutics Proxy statement: Proxy Filing


Abeona Therapeutics Earnings Call Transcript: Q2 2024

Aug 12, 2024, 8:30 AM EDT - 2 years ago

Abeona Therapeutics Earnings Call Transcript: Q2 2024


Abeona Therapeutics Quarterly report: Q2 2024

Aug 12, 2024, 8:30 AM EDT - 2 years ago

Abeona Therapeutics Quarterly report: Q2 2024


Abeona Therapeutics Earnings release: Q2 2024

Aug 12, 2024, 8:30 AM EDT - 2 years ago

Abeona Therapeutics Earnings release: Q2 2024


LorriPurdy207
LorriPurdy207 Aug. 19 at 9:13 AM
$AGQ $BIDU $NUVB $ABEO AGQ provides leveraged silver exposure, Baidu benefits from Chinese AI and cloud growth, Nuvation Bio remains focused on oncology development, and Abeona advances cell and gene therapies. I'm watching silver prices, Chinese demand, clinical milestones, regulatory catalysts, and funding.
0 · Reply
DeanPresto849
DeanPresto849 Aug. 19 at 7:15 AM
$AGQ $BIDU $NUVB $ABEO AGQ provides leveraged silver exposure, Baidu benefits from Chinese AI and cloud growth, Nuvation Bio remains focused on oncology development, and Abeona advances cell and gene therapies. I'm watching silver prices, Chinese demand, clinical milestones, regulatory catalysts, and funding.
0 · Reply
commoncentsinvestor
commoncentsinvestor Aug. 19 at 1:23 AM
$ABEO Whether Abeona Therapeutics Inc (NASDAQ: ABEO) is undervalued depends on whether you weigh Wall Street's future product expectations or current commercial execution. Trading around $6.80 to $7.20, consensus analyst price targets average roughly $18.85 to $19.71, suggesting significant upside if its gene therapy rollouts succeed. However, fundamental metrics show a mixed and speculative picture.Analyst and Intrinsic OptimismHigh Price Targets: Wall Street consensus forecasts a strong buy potential with targets ranging from a low of $14 up to $28, implying substantial percentage upside from current levels.Model-Based Upside: Certain intrinsic value models point to deep undervaluation based on long-term discounted cash flows of their therapeutic pipelin
0 · Reply
acm20
acm20 Aug. 19 at 12:00 AM
$ABEO "A buy signal was issued from a pivot bottom point on Monday, August 17, 2026, and so far it has risen 3.70%." "The stock lies in the lower part of a very wide and strong rising trend in the short term, and this may normally pose a very good buying opportunity. If the lower trend floor at $5.97 is broken, it will firstly indicate a slower rate of rising, but may also be an early warning for a trend shift. Given the current short-term trend, the stock is expected to rise 24.71% during the next 3 months and, with a 90% probability hold a price between $7.44 and $9.85 at the end of this 3-month period."
0 · Reply
TragicRain
TragicRain Aug. 18 at 8:39 PM
$ABEO - Happy Happy dance.......
0 · Reply
tmoney4572
tmoney4572 Aug. 18 at 8:14 PM
0 · Reply
Rolo2024
Rolo2024 Aug. 18 at 7:09 PM
$ABEO Better up than down. Let’s see if we can finally turn this ship around after recent earnings report.
0 · Reply
stinkypoopypantz
stinkypoopypantz Aug. 18 at 7:09 PM
$ABEO waiting for the news on this pump?!
1 · Reply
jimmy18000
jimmy18000 Aug. 18 at 7:03 PM
$ABEO moving north after couple days of take down.
1 · Reply
TerriFowler457
TerriFowler457 Aug. 18 at 11:53 AM
$ABEO $SE $POET $ONON Abeona advances cell and gene therapies, Sea benefits from e-commerce and digital-financial growth in Southeast Asia, POET develops optical-engine and photonic technologies, and On Holding benefits from premium athletic-footwear demand. I'm watching clinical catalysts, GMV growth, AI networking, and consumer spending.
0 · Reply
TragicRain
TragicRain Aug. 18 at 10:56 AM
$ABEO - SMH how many 1st year companies can bring this to the table? "Cost of sales for the second quarter of 2026 were $4.2 million, with gross margins of approximately 63%. Management expect gross margins to ultimately reach approximately 85%-90% once the facility reaches full operating capacity. At 63% in 2Q26, there appears to be meaningful potential for gross-margin expansion as manufacturing volumes increase, although the timing and magnitude of this improvement is uncertain. " Saving lives, bringing pain relief...and being a sexy gross margin already in the first year........ 10k shares is the goal.....(almost there)
0 · Reply
Estimize
Estimize Aug. 18 at 10:01 AM
Wall St is expecting -0.18 EPS for $ABEO Q3 [Reporting 11/16 BMO] http://www.estimize.com/intro/abeo?chart=historical&metric_name=eps&utm_c
0 · Reply
commoncentsinvestor
commoncentsinvestor Aug. 18 at 1:04 AM
$ABEO https://finance.yahoo.com/healthcare/articles/abeo-zevaskyn-launch-gains-momentum-150500374.html
0 · Reply
ZacksSCR
ZacksSCR Aug. 17 at 7:12 PM
$ABEO: Zevaskyn® Launch Gains Momentum
0 · Reply
tmoney4572
tmoney4572 Aug. 17 at 4:39 PM
$ABEO yall mf scared to grab your ballz and hold on. This mf has not tanked. The fact that it’s holding support right now tells you it’s primed for another run. The market knows that this is just a matter of time
0 · Reply
Filvul
Filvul Aug. 17 at 2:48 PM
$ABEO shorts and crickets for 3 months now...
1 · Reply
tmoney4572
tmoney4572 Aug. 17 at 2:37 PM
$ABEO institutions haven’t gone anywhere. Ride the shake out
0 · Reply
TragicRain
TragicRain Aug. 17 at 2:01 PM
$ABEO - My CB is under $5 - I am loving life - I am getting another opportunity to buy towards my goal of 10k shares. I dont expect to get paid tomorrow, apparently you did.... Thats on you .... So yea...super happy, I didnt believe it would get back down under $6.
0 · Reply
invest2021_now
invest2021_now Aug. 17 at 1:56 PM
$ABEO Thanks for the cheap ones, shorts!
0 · Reply
TragicRain
TragicRain Aug. 17 at 12:19 PM
$ABEO - Happy Times....Sept could be the start of another revenue stream for $ABEO with no risk on their end.....
1 · Reply
Value1008
Value1008 Aug. 17 at 5:42 AM
$ABEO - i picked up 4k shares at these low prices. Seems quite under-rated for a patient investor. I'll buy more if it drops to mid-5s
0 · Reply
gusm17
gusm17 Aug. 15 at 1:46 AM
$ABEO order flow this week and heavy volume point to accumulation vs sell off… every day was overwhelming buying and big lots…perhaps providing liquidity for shorts to cover
1 · Reply